Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(0.58)
# 4,138
Out of 5,124 analysts
9
Total ratings
42.86%
Success rate
-18.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Overweight | $8 | $1.50 | +433.33% | 1 | Jun 27, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $26.42 | -5.37% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $2.26 | +121.24% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $49.73 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $3.16 | +596.20% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $23.47 | +385.73% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $9.52 | - | 2 | Nov 15, 2021 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.50
Upside: +433.33%
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $26.42
Upside: -5.37%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $2.26
Upside: +121.24%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $49.73
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $3.16
Upside: +596.20%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $23.47
Upside: +385.73%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $9.52
Upside: -